Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...

Despite strong cash flow and organic growth in most of its key brands, high leverage and mixed valuation ratios lead to a ...

GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...

The projected market expansion presents a unique opportunity for stakeholders to invest in and prioritize the development of ...

North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...

Dr. Ernest Mario, the founding chair of the Duke University Health System Board of Directors and a leader in the ...

The Industry is on the brink of a substantial surge, with the market size expected to reach USD 100 Million in 2023 and ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.